NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
3.500
-0.140 (-3.85%)
At close: Mar 6, 2026, 4:00 PM EST
3.698
+0.198 (5.67%)
After-hours: Mar 6, 2026, 7:45 PM EST
NovaBridge Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
403.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 632.00K | 2.18M | - |
| Dec 31, 2022 | -1.55M | -15.41M | - |
| Dec 31, 2021 | 13.86M | -222.44M | -94.14% |
| Dec 31, 2020 | 236.29M | 231.99M | 5,384.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 129.42M |
| Assembly Biosciences | 37.19M |
| Entrada Therapeutics | 25.42M |
| PureTech Health | 6.39M |
| Upstream Bio | 2.80M |
| 4D Molecular Therapeutics | 120.00K |
| Altimmune | 41.00K |
NBP News
- 3 days ago - NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 - GlobeNewsWire
- 4 days ago - NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 15 days ago - NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform - GlobeNewsWire
- 17 days ago - NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer - GlobeNewsWire
- 6 weeks ago - NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei - GlobeNewsWire
- 2 months ago - NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer - GlobeNewsWire
- 2 months ago - NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 - GlobeNewsWire
- 3 months ago - NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO - GlobeNewsWire